Medivation, Inc. (NASDAQ:MDVN)
| CAPS Rating |
|
|---|---|
| Open | $67.91 |
| Previous Close | $68.71 |
| Daily Range | $67.02 - $68.25 |
| 52-Week Range | $14.32 - $76.65 |
| Market Cap | $2.37B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 706,461 |
| Average Daily Volume | 0 |
MDVN
VS S&P 500 (SPY)
How do you think MDVN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MDVN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MDVN News and Commentary
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Dendreon Gets a New CEO - Analyst Blog – NASDAQ
- Whoa! What Just Happened to My Stock? – The Motley Fool
- Medivation/Astellas' MDV3100 Shines - Analyst Blog – NASDAQ
- New CEO = Dendreon Takeover Target? – The Motley Fool
- Side Effect of Low Side Effects: 20% Stock Gain – The Motley Fool
- Medivation Shares Soared: What You Need to Know – The Motley Fool
- Medivation Prostate Cancer Drug Works Well, Appears Safe in Study – Minyanville
- FDA Approval Isn't Enough – The Motley Fool
- Dendreon Stays Neutral - Analyst Blog – NASDAQ
- Buy, Sell, or Hold: Dendreon – The Motley Fool
- A Few Stocks Weighing Down the Dow – The Motley Fool
- Zacks Bull and Bear of the Day Highlights: Lamar Advertising, HDFC Bank, Medivation, Pfizer and John – NASDAQ
- Pfizer-Medivation Call It Quits - Analyst Blog – NASDAQ
- You Can Forget About Seeing This Drug Work – The Motley Fool
- UPDATE: Medivation, Pfizer End Development Of Alzheimer's Drug – SmartMoney
- Stocks Shaking the Investment World – The Motley Fool
- The 2 Biotechs Ramping Up Sales – The Motley Fool
- 5 More Stocks That More Than Doubled in 2011 – The Motley Fool
- 2nd UPDATE: Dendreon Shares Jump On Rise In Provenge Revenue – SmartMoney
RSS Headlines
Fool UK
